Reports
The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.
MEDICAL FRONTIERS - ESMO Conference on Sarcoma and GIST
Advances in GIST Treatment: The Evolving Role of Tyrosine Kinase Inhibitors
Milan, Italy / March 9-10, 2010
Milan - A series of major advances in the treatment of gastrointestinal stromal tumours (GIST) continues with progress in determining when to conduct mutational analyses to better target tyrosine kinase inhibitors (TKIs). Although surgery...
PRIORITY PRESS - 3rd World Congress on Controversies in Urology
An Enhanced Medical Approach to Androgen Suppression in Prostate Cancer
Athens, Greece / February 25-28, 2010
Athens - It has been 70 years since investigators first understood that prostate cancer is hormone-sensitive and that medical suppression of testosterone production can control the tumour and affect long-term disease outcomes. Yet there are...
MEDICAL FRONTIERS - 32nd San Antonio Breast Cancer Symposium
Examining Cardiac Safety of Anthracyclines in Breast Cancer
San Antonio, Texas / December 10-13, 2009
San Antonio - Anthracyclines have withstood the test of time, and despite a long history of clinical use, the drug class remains among the most active therapies available for breast cancer. However, cumulative dose-related cardiotoxicity...
PRIORITY PRESS - 51st Annual Meeting of the American Society of Hematology
Enhanced Directives for Anticoagulation in Cancer Patients
New Orleans, Louisiana / December 5-8, 2009
New Orleans - Prophylaxis for venous thromboembolism (VTE) has now been endorsed for hospitalized cancer patients without a bleeding contraindication by a broad array of influential medical organizations, including the American Society of...
PRIORITY PRESS - 51st Annual Meeting of the American Society of Hematology
Optimizing Multiple Myeloma Induction and Maintenance Therapies in the Elderly
New Orleans, Louisiana / December 5-8, 2009
New Orleans - The standard of care for the treatment of multiple myeloma (MM) in elderly patients, who cannot usually tolerate high-dose therapy, was recently revised from a two-drug combination of melphalan and prednisone (MP) to a...
FRONTLINE - Based on presentations from the Second Eastern Ontario Gastrointestinal Stromal Tumours (GIST) Consensus Meeting
Second Eastern Ontario Conference on the Management of GIST
Ottawa, Ontario / November 6, 2009
Two years ago, the first eastern Ontario consensus conference on the detection, staging and treatment of gastrointestinal stromal tumours (GISTs) provided a summary of current management in the context of regional resources. A second...
PRIORITY PRESS - Society of Urologic Surgeons of Ontario Meeting
Improving Survival in Prostate Cancer Through Enhanced Androgen Suppression
Toronto, Ontario / October 21, 2009
Toronto - Therapeutic options for the treatment of prostate cancer continue to expand, from orchiectomy, the first effective treatment, through to a variety of formulations of gonadotropin-releasing hormone (GnRH) agonists and now, more...
PRIORITY PRESS - 15th European Cancer Conference and 34th ESMO Multidisciplinary Congress
New Perspectives on mTOR Inhibition in Advanced Renal Cell Carcinoma
Berlin, Germany / September 20-24, 2009
Berlin - Prior to 2000, the only treatment for advanced renal cell carcinoma (RCC) was cytokine-based therapy with either interferon-alpha or interleukin-2. Only a minority of patients with RCC responded and the outlook remained poor. A...
PRIORITY PRESS - 15th European Cancer Conference (ECCO) and 34th ESMO Multidisciplinary Congress
Six-year IES Results: New Evidence Regarding Long-term ER+ Breast Cancer Strategies
Berlin, Germany / September 20-24, 2009
Berlin - In the longest follow-up of any adjuvant breast cancer trial, women who were switched to the aromatase inhibitor exemestane from tamoxifen therapy after two to three years of treatment had a lower disease-free survival event rate...